IMMUTEP LIMITED - Announcements

5.13%

37.0¢

Market Cap $574.7M

Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

IMM	Change in substantial holding		11/02/26	1.1MB	Share
IMM	Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC	PRICE SENSITIVE	06/02/26	147.65KB	Share
IMM	Change in substantial holding		05/02/26	697.27KB	Share
IMM	Immutep Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/01/26	532.24KB	Share
IMM	Change in substantial holding		31/12/25	368.85KB	Share
IMM	Positive Update on IMP761 Phase 1	PRICE SENSITIVE	22/12/25	229.59KB	Share
IMM	TACTI-004 phase III trial enrolment continues at robust pace	PRICE SENSITIVE	16/12/25	170.64KB	Share
IMM	Immutep enters into Strategic Collaboration with Dr. Reddy's	PRICE SENSITIVE	08/12/25	235.09KB	Share
IMM	Change of Director's Interest Notice - R Howard		05/12/25	285.38KB	Share
IMM	Change of Director's Interest Notice - P Meyers		05/12/25	284.36KB	Share
IMM	Change of Director's Interest Notice - L Boyce		05/12/25	284.84KB	Share
IMM	Application for quotation of securities - IMM		05/12/25	16.36KB	Share
IMM	Notification regarding unquoted securities - IMM		02/12/25	17.18KB	Share
IMM	New data presentation from AIPAC-003 Phase II for SABCS	PRICE SENSITIVE	02/12/25	150.4KB	Share
IMM	Results of Meeting		27/11/25	172.87KB	Share
IMM	Immutep AGM 2025 - Chairman's Address		27/11/25	154.82KB	Share
IMM	Immutep AGM 2025 - CEO's Presentation		27/11/25	5.09MB	Share
IMM	EFTISARC-NEO Phase II results presented at CTOS 2025	PRICE SENSITIVE	13/11/25	168.56KB	Share
IMM	Immutep Receives A$4.6 million French R&D Tax Incentive	PRICE SENSITIVE	03/11/25	240.58KB	Share
IMM	Immutep Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/10/25	494.7KB	Share
IMM	Annual Report filed on Form 20-F		27/10/25	2.6MB	Share
IMM	Notice of Annual General Meeting/Proxy Form		24/10/25	1.74MB	Share
IMM	Appendix 4G and Corporate Governance Statement		24/10/25	894.75KB	Share
IMM	Annual Report to shareholders		24/10/25	1.15MB	Share
IMM	Improved ORR in First Line NSCLC - presented at ESMO 2025	PRICE SENSITIVE	20/10/25	176.45KB	Share
IMM	Primary Endpoint Met in STS Trial - presented at ESMO 2025	PRICE SENSITIVE	20/10/25	154.91KB	Share
IMM	2025 Annual General Meeting and Key Dates		15/10/25	426.99KB	Share
IMM	Notification regarding unquoted securities - IMM		13/10/25	15.91KB	Share
IMM	Successful Completion of FDA Project Optimus Requirements	PRICE SENSITIVE	13/10/25	146.56KB	Share
IMM	TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC	PRICE SENSITIVE	09/10/25	178.31KB	Share
IMM	Change of Director's Interest Notice - P Meyers		08/10/25	129.23KB	Share
IMM	Change of Director's Interest Notice - F Triebel		08/10/25	128.99KB	Share
IMM	Change of Director's Interest Notice - M Voigt		08/10/25	127KB	Share
IMM	Application for quotation of securities - IMM		01/10/25	16.59KB	Share
IMM	New investigator-initiated Phase II trial for Efti	PRICE SENSITIVE	22/09/25	162.41KB	Share
IMM	Becoming a substantial holder		12/09/25	786.85KB	Share
IMM	EFTISARC-NEO data accepted for oral presentation at CTOS		08/09/25	138.87KB	Share
IMM	Appendix 4E & 2025 Full Year Statutory Accounts	PRICE SENSITIVE	29/08/25	2.36MB	Share
IMM	FDA feedback received for head & neck cancer in CPS below 1	PRICE SENSITIVE	05/08/25	103.18KB	Share
IMM	Immutep Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/07/25	563.42KB	Share
IMM	TACTI-004 trial in progress poster to be presented at WCLC		29/07/25	247.77KB	Share
IMM	Abstracts Accepted for Presentation at ESMO Congress 2025		28/07/25	223.82KB	Share
IMM	Ceasing to be a substantial holder		25/07/25	937.69KB	Share
IMM	Ceasing to be a substantial holder		23/07/25	236.04KB	Share
IMM	Application for quotation of securities - IMM		18/07/25	15.6KB	Share
IMM	Application for quotation of securities - IMM		18/07/25	15.6KB	Share
IMM	Change in substantial holding		17/07/25	886.5KB	Share
IMM	Change in substantial holding		30/06/25	251.25KB	Share
IMM	Update on Phase I Study of IMP761 for Autoimmune Diseases	PRICE SENSITIVE	23/06/25	282.33KB	Share
IMM	Immutep Corporate Presentation		02/06/25	3.75MB	Share
IMM	Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial	PRICE SENSITIVE	26/05/25	204.99KB	Share
IMM	High Response Rates achieved in Lung Cancer in INSIGHT-003	PRICE SENSITIVE	15/05/25	262.28KB	Share
IMM	Excellent Overall Survival in Head & Neck Cancer Patients	PRICE SENSITIVE	05/05/25	274.92KB	Share
IMM	Change in substantial holding		01/05/25	98.74KB	Share
IMM	Immutep Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/04/25	518.27KB	Share
IMM	Immutep Investor Update		23/04/25	594.9KB	Share
IMM	Change in substantial holding		11/04/25	1.22MB	Share
IMM	Change of Director's Interest Notice - M Voigt		08/04/25	127.05KB	Share
IMM	Change of Director's Interest Notice F Triebel		08/04/25	128.98KB	Share
IMM	Application for quotation of securities - IMM		03/04/25	16.39KB	Share
IMM	Immutep to Participate in Upcoming Investor Conferences		02/04/25	174.25KB	Share
IMM	First patient dosed in phase 3 TACTI-004 lung cancer trial	PRICE SENSITIVE	25/03/25	273.27KB	Share
IMM	TACTI-004 trial in progress poster to be presented at ELCC		20/03/25	234.63KB	Share
IMM	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/25	888.77KB	Share
IMM	Notification of cessation of securities - IMM		06/02/25	12.74KB	Share
IMM	Immutep Corporate Presentation		05/02/25	3.37MB	Share
IMM	Immutep Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/01/25	400.18KB	Share
IMM	Enrolment completed for Ph II trial in Soft Tissue Sarcoma		22/01/25	97.18KB	Share
IMM	Patient Enrolment Completed for INSIGHT-003		06/01/25	262.36KB	Share
IMM	Notification of cessation of securities - IMM		17/12/24	12.73KB	Share
IMM	Immutep announces initial safety data from IMP761 phase 1	PRICE SENSITIVE	17/12/24	101.88KB	Share
IMM	Publication Detailing How Human LAG-3 Binds to MHC Class II		16/12/24	384.45KB	Share
IMM	Application for quotation of securities - IMM		13/12/24	15.75KB	Share
IMM	Immutep Reports Promising New Data in Head and Neck Cancer	PRICE SENSITIVE	12/12/24	865.06KB	Share
IMM	Change of Director's Interest Notice - L Boyce		10/12/24	125.62KB	Share
IMM	Change of Director's Interest Notice - R Howard		10/12/24	126.18KB	Share
IMM	Change of Director's Interest Notice - F Triebel		10/12/24	127.82KB	Share
IMM	Change of Director's Interest Notice - M Voigt		10/12/24	125.74KB	Share
IMM	Initiation of TACTI-004 phase 3 trial in 1st line NSCLC	PRICE SENSITIVE	10/12/24	182.79KB	Share
IMM	Application for quotation of securities - IMM		06/12/24	16.34KB	Share
IMM	Notification regarding unquoted securities - IMM		05/12/24	16.25KB	Share
IMM	Immutep Investor Update		26/11/24	1.07MB	Share
IMM	Results of Meeting		22/11/24	136.15KB	Share
IMM	Immutep AGM 2024 - CEO's Presentation		22/11/24	1.43MB	Share
IMM	Immutep AGM 2024 - Chairman's Address		22/11/24	190.03KB	Share
IMM	Change in substantial holding		18/11/24	91.09KB	Share
IMM	Excellent Survival Data from INSIGHT-003 Trial in NSCLC	PRICE SENSITIVE	14/11/24	299.39KB	Share
IMM	Positive Data from Phase II Trial in Soft Tissue Sarcoma	PRICE SENSITIVE	14/11/24	262.09KB	Share
IMM	Becoming a substantial holder		14/11/24	606.6KB	Share
IMM	Immutep Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/10/24	1.02MB	Share
IMM	TACTI-003 Cohort B data to be presented at ESMO I-O		28/10/24	179.92KB	Share
IMM	Annual Report filed on Form 20-F with SEC		23/10/24	780.19KB	Share
IMM	Notice of Annual General Meeting/Proxy Form		22/10/24	1.42MB	Share
IMM	Appendix 4G and Corporate Governance Statement		22/10/24	603.94KB	Share
IMM	Annual Report to shareholders		22/10/24	1.03MB	Share
IMM	Ceasing to be a substantial holder		21/10/24	506.67KB	Share
IMM	Change in substantial holding		18/10/24	340.14KB	Share
IMM	Becoming a substantial holder		17/10/24	1.95MB	Share
IMM	IMP761 Progresses to Dose Escalation Portion of Ph1 Trial		17/10/24	232.21KB	Share
IMM	Appendix 3Z - Anne Anderson		14/10/24	107.5KB	Share

IMM Change in substantial holding
11/02/26		1.1MB	Share
IMM Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
06/02/26	PRICE SENSITIVE	147.65KB	Share
IMM Change in substantial holding
05/02/26		697.27KB	Share
IMM Immutep Quarterly Activities Report and Appendix 4C
29/01/26	PRICE SENSITIVE	532.24KB	Share
IMM Change in substantial holding
31/12/25		368.85KB	Share
IMM Positive Update on IMP761 Phase 1
22/12/25	PRICE SENSITIVE	229.59KB	Share
IMM TACTI-004 phase III trial enrolment continues at robust pace
16/12/25	PRICE SENSITIVE	170.64KB	Share
IMM Immutep enters into Strategic Collaboration with Dr. Reddy's
08/12/25	PRICE SENSITIVE	235.09KB	Share
IMM Change of Director's Interest Notice - R Howard
05/12/25		285.38KB	Share
IMM Change of Director's Interest Notice - P Meyers
05/12/25		284.36KB	Share
IMM Change of Director's Interest Notice - L Boyce
05/12/25		284.84KB	Share
IMM Application for quotation of securities - IMM
05/12/25		16.36KB	Share
IMM Notification regarding unquoted securities - IMM
02/12/25		17.18KB	Share
IMM New data presentation from AIPAC-003 Phase II for SABCS
02/12/25	PRICE SENSITIVE	150.4KB	Share
IMM Results of Meeting
27/11/25		172.87KB	Share
IMM Immutep AGM 2025 - Chairman's Address
27/11/25		154.82KB	Share
IMM Immutep AGM 2025 - CEO's Presentation
27/11/25		5.09MB	Share
IMM EFTISARC-NEO Phase II results presented at CTOS 2025
13/11/25	PRICE SENSITIVE	168.56KB	Share
IMM Immutep Receives A$4.6 million French R&D Tax Incentive
03/11/25	PRICE SENSITIVE	240.58KB	Share
IMM Immutep Quarterly Activities Report and Appendix 4C
29/10/25	PRICE SENSITIVE	494.7KB	Share
IMM Annual Report filed on Form 20-F
27/10/25		2.6MB	Share
IMM Notice of Annual General Meeting/Proxy Form
24/10/25		1.74MB	Share
IMM Appendix 4G and Corporate Governance Statement
24/10/25		894.75KB	Share
IMM Annual Report to shareholders
24/10/25		1.15MB	Share
IMM Improved ORR in First Line NSCLC - presented at ESMO 2025
20/10/25	PRICE SENSITIVE	176.45KB	Share
IMM Primary Endpoint Met in STS Trial - presented at ESMO 2025
20/10/25	PRICE SENSITIVE	154.91KB	Share
IMM 2025 Annual General Meeting and Key Dates
15/10/25		426.99KB	Share
IMM Notification regarding unquoted securities - IMM
13/10/25		15.91KB	Share
IMM Successful Completion of FDA Project Optimus Requirements
13/10/25	PRICE SENSITIVE	146.56KB	Share
IMM TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC
09/10/25	PRICE SENSITIVE	178.31KB	Share
IMM Change of Director's Interest Notice - P Meyers
08/10/25		129.23KB	Share
IMM Change of Director's Interest Notice - F Triebel
08/10/25		128.99KB	Share
IMM Change of Director's Interest Notice - M Voigt
08/10/25		127KB	Share
IMM Application for quotation of securities - IMM
01/10/25		16.59KB	Share
IMM New investigator-initiated Phase II trial for Efti
22/09/25	PRICE SENSITIVE	162.41KB	Share
IMM Becoming a substantial holder
12/09/25		786.85KB	Share
IMM EFTISARC-NEO data accepted for oral presentation at CTOS
08/09/25		138.87KB	Share
IMM Appendix 4E & 2025 Full Year Statutory Accounts
29/08/25	PRICE SENSITIVE	2.36MB	Share
IMM FDA feedback received for head & neck cancer in CPS below 1
05/08/25	PRICE SENSITIVE	103.18KB	Share
IMM Immutep Quarterly Activities Report and Appendix 4C
30/07/25	PRICE SENSITIVE	563.42KB	Share
IMM TACTI-004 trial in progress poster to be presented at WCLC
29/07/25		247.77KB	Share
IMM Abstracts Accepted for Presentation at ESMO Congress 2025
28/07/25		223.82KB	Share
IMM Ceasing to be a substantial holder
25/07/25		937.69KB	Share
IMM Ceasing to be a substantial holder
23/07/25		236.04KB	Share
IMM Application for quotation of securities - IMM
18/07/25		15.6KB	Share
IMM Application for quotation of securities - IMM
18/07/25		15.6KB	Share
IMM Change in substantial holding
17/07/25		886.5KB	Share
IMM Change in substantial holding
30/06/25		251.25KB	Share
IMM Update on Phase I Study of IMP761 for Autoimmune Diseases
23/06/25	PRICE SENSITIVE	282.33KB	Share
IMM Immutep Corporate Presentation
02/06/25		3.75MB	Share
IMM Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial
26/05/25	PRICE SENSITIVE	204.99KB	Share
IMM High Response Rates achieved in Lung Cancer in INSIGHT-003
15/05/25	PRICE SENSITIVE	262.28KB	Share
IMM Excellent Overall Survival in Head & Neck Cancer Patients
05/05/25	PRICE SENSITIVE	274.92KB	Share
IMM Change in substantial holding
01/05/25		98.74KB	Share
IMM Immutep Quarterly Activities Report and Appendix 4C
29/04/25	PRICE SENSITIVE	518.27KB	Share
IMM Immutep Investor Update
23/04/25		594.9KB	Share
IMM Change in substantial holding
11/04/25		1.22MB	Share
IMM Change of Director's Interest Notice - M Voigt
08/04/25		127.05KB	Share
IMM Change of Director's Interest Notice F Triebel
08/04/25		128.98KB	Share
IMM Application for quotation of securities - IMM
03/04/25		16.39KB	Share
IMM Immutep to Participate in Upcoming Investor Conferences
02/04/25		174.25KB	Share
IMM First patient dosed in phase 3 TACTI-004 lung cancer trial
25/03/25	PRICE SENSITIVE	273.27KB	Share
IMM TACTI-004 trial in progress poster to be presented at ELCC
20/03/25		234.63KB	Share
IMM Half Yearly Report and Accounts
26/02/25	PRICE SENSITIVE	888.77KB	Share
IMM Notification of cessation of securities - IMM
06/02/25		12.74KB	Share
IMM Immutep Corporate Presentation
05/02/25		3.37MB	Share
IMM Immutep Quarterly Activities Report and Appendix 4C
31/01/25	PRICE SENSITIVE	400.18KB	Share
IMM Enrolment completed for Ph II trial in Soft Tissue Sarcoma
22/01/25		97.18KB	Share
IMM Patient Enrolment Completed for INSIGHT-003
06/01/25		262.36KB	Share
IMM Notification of cessation of securities - IMM
17/12/24		12.73KB	Share
IMM Immutep announces initial safety data from IMP761 phase 1
17/12/24	PRICE SENSITIVE	101.88KB	Share
IMM Publication Detailing How Human LAG-3 Binds to MHC Class II
16/12/24		384.45KB	Share
IMM Application for quotation of securities - IMM
13/12/24		15.75KB	Share
IMM Immutep Reports Promising New Data in Head and Neck Cancer
12/12/24	PRICE SENSITIVE	865.06KB	Share
IMM Change of Director's Interest Notice - L Boyce
10/12/24		125.62KB	Share
IMM Change of Director's Interest Notice - R Howard
10/12/24		126.18KB	Share
IMM Change of Director's Interest Notice - F Triebel
10/12/24		127.82KB	Share
IMM Change of Director's Interest Notice - M Voigt
10/12/24		125.74KB	Share
IMM Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
10/12/24	PRICE SENSITIVE	182.79KB	Share
IMM Application for quotation of securities - IMM
06/12/24		16.34KB	Share
IMM Notification regarding unquoted securities - IMM
05/12/24		16.25KB	Share
IMM Immutep Investor Update
26/11/24		1.07MB	Share
IMM Results of Meeting
22/11/24		136.15KB	Share
IMM Immutep AGM 2024 - CEO's Presentation
22/11/24		1.43MB	Share
IMM Immutep AGM 2024 - Chairman's Address
22/11/24		190.03KB	Share
IMM Change in substantial holding
18/11/24		91.09KB	Share
IMM Excellent Survival Data from INSIGHT-003 Trial in NSCLC
14/11/24	PRICE SENSITIVE	299.39KB	Share
IMM Positive Data from Phase II Trial in Soft Tissue Sarcoma
14/11/24	PRICE SENSITIVE	262.09KB	Share
IMM Becoming a substantial holder
14/11/24		606.6KB	Share
IMM Immutep Quarterly Activities Report and Appendix 4C
29/10/24	PRICE SENSITIVE	1.02MB	Share
IMM TACTI-003 Cohort B data to be presented at ESMO I-O
28/10/24		179.92KB	Share
IMM Annual Report filed on Form 20-F with SEC
23/10/24		780.19KB	Share
IMM Notice of Annual General Meeting/Proxy Form
22/10/24		1.42MB	Share
IMM Appendix 4G and Corporate Governance Statement
22/10/24		603.94KB	Share
IMM Annual Report to shareholders
22/10/24		1.03MB	Share
IMM Ceasing to be a substantial holder
21/10/24		506.67KB	Share
IMM Change in substantial holding
18/10/24		340.14KB	Share
IMM Becoming a substantial holder
17/10/24		1.95MB	Share
IMM IMP761 Progresses to Dose Escalation Portion of Ph1 Trial
17/10/24		232.21KB	Share
IMM Appendix 3Z - Anne Anderson
14/10/24		107.5KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 37.0¢		Change -0.020(5.13%)		Mkt cap ! $574.7M

Open	High	Low	Volume
39.5¢	39.5¢	37.0¢	1.820M

Buyers (Bids)

Vol.	Price($)
127540	37.0¢

Sellers (Offers)

Price($)	Vol.
38.0¢	25641

Last trade - 16.19pm 12/02/2026 (20 minute delay)

IMM (ASX) Chart

IMMUTEP LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available